Hyderabad, India and Princeton, NJ, USA. July 11, 2018— Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Hydroxychloroquine Sulfate Tablets USP, 200 mg, a therapeutic equivalent generic version of Plaquenil® (hydroxychloroquine sulfate) Tablets, in the U.S. market, approved by the U.S. Food and Drug Administration (USFDA).
The Plaquenil® brand and generic had U.S. sales of approximately $215 million MAT for the most recent twelve months ending in May 2018 according to IMS Health*.
Dr. Reddy’s Hydroxychloroquine Sulfate Tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
Plaquenil® is a trademark of Concordia International Corp.
Your email address will not be published. Required fields are marked *
FTC Celebrates 100th Anniversary of its Regional Offices
Australian Military Bank Powers Digital Transformation with Infosys Finacle on Cloud
Alpana Kirloskar honoured with IWEC Award in Shanghai, China
TCS Democratizes Recruitment to Provide an Equal Opportunity to Young Engineers across India
Schneider Electric strengthens strategic partnerships with top suppliers
2014 The Global Indian New Network (TGINN)